Hepatocellular carcinoma (HCC) is one of the most common causes for cancerrelated death worldwide with rapidly increasing incidence and mortality rates. As for other types of cancers, also in HCC cancer stem cells (CSCs) are thought to be responsible for tumour initiation, progression and therapy failure. However, as rare subpopulations of tumour tissue, CSCs are difficult to isolate, thus making the development of suitable and reliable model systems necessary. In our study, we 
| INTRODUCTION
Hepatocellular carcinomas (HCCs) represent the most common type of liver cancer and one of the leading causes of cancer-related deaths worldwide, having the most rapidly rising incidence and mortality rates when compared to other types of cancer. [1] [2] [3] [4] [5] [6] In general, HCC tumours are genetically and phenotypically very heterogeneous as they arise from a background of different chronic pathological conditions such as liver cirrhosis and fibrosis that are most frequently associated with hepatitis B or hepatitis C virus infections, alcoholic liver diseases or metabolic disorders. 1, 7, 8 Although there are various treatment strategies available, including conventional chemotherapy, surgical resection, liver transplantation and radiother-chemotherapeutics, the major reasons for poor patient outcome and high mortality rates associated with HCC are resistance to conventional anticancer therapy, a high frequency of recurrences and the formation of metastases. 1, 4, [8] [9] [10] [11] As for other types of cancers also HCC tumours are thought to arise from so called cancer stem cells (CSCs) that represent a small sub-population of tumour cells with stem cell-like characteristics.
These include unlimited self-renewal capacity and the ability to differentiate into multiple tumour cell subtypes, which contributes to tumour heterogeneity. 1, [12] [13] [14] [15] [16] In addition to tumour initiation and continuous tumour growth, hepatic cancer stem cells (HCSCs) are also thought to be responsible for tumour progression and metastatic spread. They are resistant to conventional chemo-or radiotherapy and remain in the healthy tissue after surgical resection of primary tumours, thus being majorly responsible for HCC recurrences. 1, [15] [16] [17] [18] However, the specific roles of HCSCs and the mechanisms by which they act during individual stages of tumour growth and progression are still poorly understood. This hinders the development of efficacious HCSC-targeting therapies for HCC patients that would eradicate CSC populations and promote a better patient outcome. To detect and specifically target certain HCSCs, it is first necessary to clearly identify highly aggressive CSC sub-populations, analyse their cellular and signalling functions and finally elucidate their involvement in the individual processes of tumour initiation, progression and metastasis. Within the frame of current CSC research numerous markers including the cell surface proteins CD133 19, 20 and CD90, 21 the detoxifying enzyme aldehyde dehydrogenase (ALDH) 22 or the epithelial cell adhesion molecule (EpCAM) 23, 24 have been identified and correlated with certain stem cell characteristics. Although distinct combinations of markers could be linked to specific aggressive HCSC sub-populations using both in vitro and in vivo studies, so far it remains a major challenge to identify reliable CSC-specific biomarker sets that can eventually be applied in a clinical setting to improve HCC diagnosis and treatment strategies. 1, [15] [16] [17] [18] To better understand the role of CSCs during HCC initiation, growth, progression and drug resistance suitable and reliable model systems are required. These models will enable researchers to correlate certain CSC fractions to prognosis and to eventually develop novel HCSC biomarker sets as well as efficient CSC-targeting treatment strategies. Mostly due to their ease of use and reasonable costs, cell culture based models represent the most frequent systems used to study CSCs and CSC associated features or mechanisms. 25 In our study, we aimed to generate novel CSC enriched monoclonal cell lines of the well-established HCC cell line HepG2. For this, we utilized the spheroid formation assay, which represents a commonly accepted method to enrich CSC populations. [25] [26] [27] Our strategy gave rise to three distinct HepG2 sub-cell lines, of which two HCSC enriched subclones were selected for detailed characterization. We could verify the suitability of our novel monoclonal sub-cell lines as reliable, versatile and clinically relevant tools to investigate HCSC properties and aggressiveness by phenotypical and functional characterization both in vitro and in vivo in the chorioallantoic membrane (CAM) assay. 
| MATERIALS AND METHODS

| Spheroid migration/invasion assay
To assess the migratory potential of our HCSC enriched clones 3 and 5 in comparison to that of the parental HepG2 cells, we utilized an adapted spheroid migration assay protocol. [28] [29] [30] with at least three replicates per individual experiment and cell line depending on the spheroid formation capability. The migration assay was performed with the following total number of replicates: HepG2 -n = 6 (3/3), K3: n = 9 (5/4), K5: n = 12 (7/5).
Spheroid invasion assays can be applied to analyse the invasiveness of cell lines in vitro. [30] [31] [32] Information for details). The spheroid invasion assay was carried out in two independent experiments with a total of 11 or 12
replicates per cell line (HepG2-n = 12 (6/6), K3: n = 11 (6/5), K5: n = 11 (6/5)).
| Chorioallantoic membrane xenograft assay
The chorioallantoic membrane (CAM) assay represents a suitable and reliable alternative xenograft system to assess the in vivo growth and aggressiveness of tumour cells. 33, 34 To were fixed in 4% phosphate buffered formalin for 24 hours, dehydrated and embedded in paraffin.
| In vivo metastasis potential analysis by fluorescence imaging
To analyse the metastatic potential of clone five cells in comparison to the parental HepG2 cell line in vivo, the CAM assay was performed as described above, but using cells that were pre-stained 
| Statistical analysis
All statistical analyses were performed with GraphPad Prism 7
(GraphPad Software, Inc., La Jolla, CA, USA). Values represent means ± SD and statistical analysis was performed with two-way ANOVA, followed by Dunnett's multiple comparisons test (HepG2: n = 6, clone 3: n = 9, clone 5: n = 12). *P < 0.05, **P < 0.01, ***P < 0.001 phenotype as verified by the detection of the liver-specific markers α-fetoprotein (AFP) and albumin, which are expressed at levels similar to those of the HepG2 cells. In contrast, clones 2, 3 and 5 exhibit a varied expression of the HCSC marker CD133. While the CD133 expression level in clone 3 was comparable to that of the parental HepG2 cells, this HCSC marker was strongly increased in clone 5, but apparently hardly expressed in clone 2. As CD133 represents one of the most commonly described HCSC markers that has been associated with self-renewal capacity and tumorigenicity as well as drug-resistance mechanisms, invasiveness, metastasis and poor prognosis, [17] [18] [19] [20] we decided to focus on the two clearly CD133 positive clones 3 and 5. We verified the expression levels of CD133 and also evaluated the expression of two additional CSC markers ( Figure S1 ), namely Nanog and Oct-4, by qRT-PCR. The mRNA expression of Nanog and Oct-4 was increased in both clone 3 and clone 5, but a significantly elevated mRNA level could only be observed for Oct-4 in clone 5 cells.
| HCSC enriched clones show high cellular plasticity in vitro
Next, we investigated cell morphological features of the generated Values represent means ± SD and statistical analysis was performed with two-way ANOVA followed by Dunnett's multiple comparisons test. (HepG2: n = 12, clone 3: n = 11, clone 5: n = 11). **P < 0.01, ***P < 0.001 staining (Figure 2A,B) . While the parental HepG2 cells mainly grow as colonies in a monolayer, we could observe that both clone 3 and clone 5 cells have a higher tendency to form 3D structures. In this context, spheroid-like clusters formed in cultures of both HepG2 subclones as exemplarily shown for clone 3 (asterisks in Figure 2A ).
In contrast to the parental HepG2 and clone 3 cells, which exhibited very similar rounded cell morphologies, clone 5 cultures showed large fractions of cells with a more bi-or tripolar morphology as well as elongated cell protrusions (arrows in Figure 2A ,B).
Fluorescence staining analysis revealed a more diffuse organization of the actin cytoskeleton and apparently an increase in the cytoplasmic/nuclear ratio for clone 3 and clone 5 when compared to HepG2 cells ( Figure 2B ). In addition, it should be noted that a similar expression level of the liver-specific marker AFP could also be detected by immunofluorescence in all three investigated HepG2 cell lines corroborating our Western Blot data ( Figures 1D and 2B ).
Since the aggressiveness of tumour cells with certain CSC phenotypes has largely been associated with high tumour cell plasticity such as the epithelial-mesenchymal transition (EMT) and the formation of vasculogenic mimicry, [36] [37] [38] [39] we subjected the HCSC enriched HepG2 clones 3 and 5 to a Matrigel-based tube formation assay.
Assessing their potential to generate 3D networks, we could indeed observe that the HCSC enriched clones display a much higher cell plasticity than the parental HepG2 cell line ( Figure 2C ). While 
| HCSC enriched clones show a highly migratory and invasive potential in vitro
Tumour cell motility largely contributes to invasion and metastasis of tumours and can hence be applied as a measure for aggressiveness. 42, 43 The migratory potential of the HCSC enriched clones 3 and 5 was assessed in a spheroid migration assay in comparison to
HepG2 cells by determination of the migration area surrounding the spheroid (blue, Figure 3A) relative to the respective spheroid core size over time (red, Figure 3A) . The spheroids of clones 3 and 5 were approximately twofold bigger in size (A Core ) than those of the parental cell line throughout the whole experimental period (Figure 3B) . In terms of migratory potential, clone 5 showed the highest cell motility, whereas the migratory potential of clone 3 was comparable or even a little lower than that of the parental HepG2 cells ( Figure 3C ).
To assess the invasive behavior of the cell lines in vitro, we per- Hence, the investigation of HCSCs and detailed elucidation of their role in tumour initiation, progression, metastasis and drug resistance has become a major focus in HCC research. 1, 13, [15] [16] [17] [18] As rare subpopulations of tumour tissue CSCs are difficult to isolate and study, so that the development of suitable and reliable cell culture model systems is required. 25 These models can then be used to better understand the role of HCSCs during carcinogenesis and tumour progression. In turn, this improved understanding will eventually allow us to identify novel treatment strategies that efficiently target highly aggressive and resistant HCSC subpopulations being responsible for therapy failure. 25 In our present study, we successfully generated two HepG2 derived monoclonal tumour cell lines, namely clone 3 and clone 5, with enhanced CSC potential by application of the tumour sphere formation assay, which represents a commonly accepted method to enrich CSC populations, [25] [26] [27] and subsequent single-cell cloning. The established clones 3 and 5 were positive for the cell surface protein CD133, which is one of the most commonly described HCSC markers. It is associated with self-renewal capacity, tumorigenicity, chemoresistance, invasiveness, tumour angiogenesis and metastasis. [16] [17] [18] [19] [20] 46 In addition, a higher expression of the CSC markers Nanog and Oct-4 could be observed, which are known to be preferentially co-expressed in CD133 + HCSCs and to be involved in the induction of EMT. 1, 17, 47, 48 To confirm the stemness state and Taken all together and in accordance with literature, 44, [52] [53] [54] our data indicate that the combination of an enhanced CSC potential and EMT(-like) features that contribute to migration and invasion also seems to be largely responsible for a highly aggressive and metastatic phenotype in our HCSC model system both in vitro and in vivo.
In conclusion, we successfully demonstrated that characteristic 
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